New DTC platforms like LillyDirect and PfizerForAll are triggering a paradigm shift in how pharma companies connect with ...

AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.64, payable on Friday, Feb. 14. That is almost 6% higher than the prior payout. The company ...

February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks ...

Ubrelvy (ubrogepant) and Nurtec (rimegepant) are prescription medications approved to help manage and offer relief for people dealing with migraine headaches with or without aura. Both belong to a ...

Ubrelvy (ubrogepant) and Nurtec (rimegepant) are prescription medications approved to help manage and offer relief for people dealing with migraine headaches with or without aura. Both belong to a ...

Related Migraine drug Ubrelvy may stop headaches at first sign Women's migraines might develop from high blood pressure, study finds Migraine med might stop 'rebound' headaches as well But just ...

AbbVie’s other key drugs, Venclexta and Vraylar, coupled with significant contributions from newer drugs Ubrelvy, Elahere and Qulipta, also pushed top-line growth. AbbVie issued an impressive ...

Ibuprofen—commonly known by the brand names Advil or Motrin—can be obtained over the counter (OTC) or with a prescription from your healthcare provider. When taking ibuprofen, it is always important ...

a Represents net earnings attributable to AbbVie Inc. Intangible asset impairment primarily reflects partial impairment charges related to the U.S. Imbruvica and CoolSculpting intangible assets ...

We now expect Skyrizi and Rinvoq to exceed more than $31 billion of combined sales in 2027, which is $4 billion above the guidance we provided last year. Skyrizi and Rinvoq together already hold ...

Botox Therapeutic net revenues were $873 million, an increase of 13% on an operational basis, Vraylar net revenues were $924 million, an increase of 17.1%, Ubrelvy net revenues were $303 million ...